Skip to main content
Journal cover image

Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.

Publication ,  Journal Article
Belina, ME; Driscoll, TA; Blanchard, SK; Cardones, AR
Published in: Pediatr Dermatol
May 2022

Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. Systemic corticosteroids remain first-line treatment for cutaneous cGVHD; however, there is currently no consensus on second-line therapy for steroid-refractory disease. We herein present a case of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, who was successfully treated with a prolonged course of ruxolitinib with minimal side effects.

Duke Scholars

Published In

Pediatr Dermatol

DOI

EISSN

1525-1470

Publication Date

May 2022

Volume

39

Issue

3

Start / End Page

432 / 433

Location

United States

Related Subject Headings

  • Steroids
  • Retrospective Studies
  • Pyrimidines
  • Pyrazoles
  • Nitriles
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
  • Dermatology & Venereal Diseases
  • Chronic Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Belina, M. E., Driscoll, T. A., Blanchard, S. K., & Cardones, A. R. (2022). Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease. Pediatr Dermatol, 39(3), 432–433. https://doi.org/10.1111/pde.14965
Belina, Morgan E., Timothy A. Driscoll, Sarah K. Blanchard, and Adela R. Cardones. “Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.Pediatr Dermatol 39, no. 3 (May 2022): 432–33. https://doi.org/10.1111/pde.14965.
Belina ME, Driscoll TA, Blanchard SK, Cardones AR. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease. Pediatr Dermatol. 2022 May;39(3):432–3.
Belina, Morgan E., et al. “Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.Pediatr Dermatol, vol. 39, no. 3, May 2022, pp. 432–33. Pubmed, doi:10.1111/pde.14965.
Belina ME, Driscoll TA, Blanchard SK, Cardones AR. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease. Pediatr Dermatol. 2022 May;39(3):432–433.
Journal cover image

Published In

Pediatr Dermatol

DOI

EISSN

1525-1470

Publication Date

May 2022

Volume

39

Issue

3

Start / End Page

432 / 433

Location

United States

Related Subject Headings

  • Steroids
  • Retrospective Studies
  • Pyrimidines
  • Pyrazoles
  • Nitriles
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
  • Dermatology & Venereal Diseases
  • Chronic Disease